Berger NA

Besson VC

Boulares AH

Burkle A

Chiarugi A

Clark RS

Curtin NJ

Cuzzocrea S

Dawson TM

Dawson VL

Hasko G

Liaudet L

Moroni F

Pacher P

Radermacher P

Salzman AL

Snyder SH

Soriano FG

Strosznajder RP

Sumegi B

Swanson RA

Szabo C

\ua9 2017 The British Pharmacological Society. The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson\u27s disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors

Newcastle University E-Prints

Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints